{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:31:17Z","timestamp":1749047477455,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02969-0","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T13:01:47Z","timestamp":1712408507000},"page":"865-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-6050","authenticated-orcid":false,"given":"Meghan E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan P.","family":"Jaynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"21","key":"2969_CR1","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D (2018) Diagnosis and management of the Antiphospholipid Syndrome. N Engl J Med 378(21):2010\u20132021. https:\/\/doi.org\/10.1056\/NEJMra1705454","journal-title":"N Engl J Med"},{"issue":"25","key":"2969_CR2","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","volume":"135","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA\/ACC focused update of the 2014 AHA\/ACC Guideline for the management of patients with Valvular Heart Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation 135(25):e1159\u2013e1195. https:\/\/doi.org\/10.1161\/CIR.0000000000000503","journal-title":"Circulation"},{"issue":"6","key":"2969_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308\u20131313. https:\/\/doi.org\/10.1111\/jth.13323","journal-title":"J Thromb Haemost"},{"key":"2969_CR4","doi-asserted-by":"publisher","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A et al (2021) 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in J Am Coll Cardiol. ;77(21):2760]. J Am Coll Cardiol. 2020;76(5):594\u2013622. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.053","DOI":"10.1016\/j.jacc.2020.04.053"},{"issue":"2","key":"2969_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11239-007-0048-2","volume":"25","author":"JD Lindh","year":"2008","unstructured":"Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A (2008) Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 25(2):151\u2013159. https:\/\/doi.org\/10.1007\/s11239-007-0048-2","journal-title":"J Thromb Thrombolysis"},{"key":"2969_CR6","unstructured":"KCentra [package insert] (2013) Marburg, Germany: CSL Behring GmbH"},{"key":"2969_CR7","doi-asserted-by":"publisher","first-page":"107602947474","DOI":"10.1177\/1076029620947474","volume":"26","author":"DH Rhoney","year":"2020","unstructured":"Rhoney DH, Chester KW (2020) Optimal dosage and Administration Practices for Vitamin K Antagonist reversal with 4-Factor Prothrombin Complex Concentrate. Clin Appl Thromb Hemost 26:107602947474 Published 2020 Oct 14. https:\/\/doi.org\/10.1177\/1076029620947474","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2969_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1538-7836.2008.02904.x","volume":"6","author":"I Pabinger","year":"2008","unstructured":"Pabinger I, Brenner B, Kalina U et al (2008) Prothrombin complex concentrate (Beriplex P\/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6(4):622\u2013631. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.02904.x","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2969_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ajem.2015.05.017","volume":"33","author":"L Klein","year":"2015","unstructured":"Klein L, Peters J, Miner J, Gorlin J (2015) Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med 33(9):1213\u20131218. https:\/\/doi.org\/10.1016\/j.ajem.2015.05.017","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2969_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11239-017-1586-x","volume":"45","author":"G Astrup","year":"2018","unstructured":"Astrup G, Sarangarm P, Burnett A (2018) Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis. J Thromb Thrombolysis 45(2):300\u2013305. https:\/\/doi.org\/10.1007\/s11239-017-1586-x","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2969_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ajem.2019.12.005","volume":"38","author":"BW Gilbert","year":"2020","unstructured":"Gilbert BW, Morton L, Huffman JB et al (2020) Modified version of the American College of Cardiology\u2019s recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal. Am J Emerg Med 38(4):806\u2013809. https:\/\/doi.org\/10.1016\/j.ajem.2019.12.005","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2969_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11239-019-01984-w","volume":"50","author":"L Fuh","year":"2020","unstructured":"Fuh L, Goldstein JN, Hayes BD (2020) Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol. J Thromb Thrombolysis 50(1):217\u2013220. https:\/\/doi.org\/10.1007\/s11239-019-01984-w","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2969_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","volume":"24","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ 3rd, Rabinstein AA et al (2016) Guideline for reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24(1):6\u201346","journal-title":"Neurocrit Care"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02969-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02969-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02969-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:14:58Z","timestamp":1720516498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02969-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2969"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02969-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"8 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB-approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"s: MEP, SB, MJ, and CM have no relevant conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}}]}}